Mice, Mergers, and Molecules: A New Discovery Pact

FairJourney Bio and AbTherx partner to deliver fully integrated antibody discovery across Porto, Cambridge, and San Diego

30 Jun 2026

FairJourney Bio and AbTherx announced a partnership on June 23, 2026, that brings transgenic mouse-based antibody discovery fully in-house. Gone are the costly handoffs between research stages that have long slowed early drug development. It is a meaningful shift, and one the industry has been circling for years.

Under the agreement, FairJourney Bio gains access to AbTherx's proprietary Atlas Full Human Diversity and Common Light Chain mouse technologies. These platforms extend an already capable workflow into a single, continuous operation built for speed. Three sites now share the load: Porto, Cambridge, and San Diego.

Running from immunization through developability assessment and cell-line development, the pipeline consolidates an expansive process under one roof. That is a strategic shift for partners chasing faster, more predictable timelines. Fewer transitions between organizations typically means lower attrition risk and steadier data continuity across a program's life.

Chief Executive Officer Dr. Werner Lanthaler framed the ambition clearly. "We are investing so a partner's programme can run from immunisation to a developability-assessed lead inside FJBio, without changing hands," he said. "Following a molecule under one roof and with one team of scientists increases probabilities of success significantly."

For biotech and pharmaceutical companies outsourcing early discovery, the deal targets a familiar bottleneck. Fragmentation costs money and time. When immunization, screening, and optimization happen at separate vendors, programs stall, miscommunication creeps in, and inconsistency erodes both data quality and timelines. Consolidating those steps within one partner's platform, backed by proven mouse technologies, cuts that friction substantially.

AbTherx brings transgenics that generate fully human antibodies with broad diversity, essential for identifying strong leads efficiently. FairJourney Bio's three-continent footprint adds reach across major biopharma markets. Together, the two companies signal something larger: a contract research industry where integrated capability, not isolated services, now decides who wins.